Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950819 · ClinicalTrials.gov registry record · Phase 4
Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,037
- Enrollment target
NCT01950819 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,037 participants.
The verdict
NCT01950819, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,037 participants
- Enrollment target
Study Summary
This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.
Interventions
- DRUG Corticosteroids
- BIOLOGICAL Induction therapy
- DRUG EVR+rCNI
- DRUG MPA+sCNI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,037 participants |
| Start Date | 2013-12-03 |
| Est. Completion | 2018-01-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01950819
The ClinicalTrials.gov registry entry for NCT01950819 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,037 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Corticosteroids is the first listed.
NCT01950819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01950819 about?
NCT01950819 is a clinical study titled "Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)". This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.
What is the current status of trial NCT01950819?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,037 participants. The study started on 2013-12-03. Estimated completion is 2018-01-17.
What interventions are being tested in trial NCT01950819?
The interventions under investigation include: Corticosteroids (DRUG), Induction therapy (BIOLOGICAL), EVR+rCNI (DRUG), MPA+sCNI (DRUG).
Who is sponsoring clinical trial NCT01950819?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.